Ketamine as a Novel Antidepressant for Treatment-Resistant Depression in Adolescents

Speaker:
Michael H. Bloch, MD, MS
Associate Professor • Director and Co-Founder, Pediatric Depression Clinic • Co-Director, T32 Postdoctoral Research Fellowship in Childhood Neuropsychiatric Disorders • Associate Program Director, Albert J. Solnit Integrated Training Program • Co-Director, Tic and OCD Program • Child Study Center • Yale School of Medicine
________
Learning objectives:
Upon completion of this activity, participants will be able to:
• Identify two medications that have been approved for the treatment of pediatric depression.
• Describe the indications, time-course of response and potential side effects of SSRI in pediatric populations.
• Describe the time-course and magnitude of antidepressant effects of ketamine in adults with depression.
• Name three clinically important unanswered questions in pediatric depression psychopharmacology.
________
Child and Adolescent Psychiatry and Behavioral Services Grand Rounds presentations are for educational purposes and intended only for behavioral/mental health professionals and clinical providers.